Roxadustat HIF-PHI Oral Anemia Drug Shows Superior Outcomes to ESAs in Chronic Kidney Disease: 3-Year Data

What Is Roxadustat and How Does It Treat Anemia Differently Than EPO Injections?

Roxadustat belongs to a novel class of drugs called hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). Under normal oxygen conditions, HIF is rapidly degraded by prolyl hydroxylase enzymes. Roxadustat inhibits these enzymes, stabilizing HIF and triggering the same transcriptional cascade that occurs at high altitude: increased endogenous erythropoietin production, enhanced iron absorption from the gut, improved iron mobilization from stores, and suppression of hepcidin — the master regulator of iron metabolism that is pathologically elevated in CKD.

The roxadustat Phase 3 clinical program comprised multiple large randomized trials — including the ALPS, ANDES, ROCKIES, HIMALAYAS, PYRENEES, and DOLOMITES studies — enrolling thousands of patients with CKD stages 3–5 (both dialysis-dependent and non-dialysis). In landmark trials published in the New England Journal of Medicine, roxadustat demonstrated effective hemoglobin correction and maintenance within guideline-recommended targets of 10–12 g/dL. Pooled analyses have shown that roxadustat achieves comparable hemoglobin targets to standard ESA therapy, with less hemoglobin variability. The reduced hemoglobin cycling is clinically meaningful, as wide hemoglobin fluctuations have been associated with increased cardiovascular risk in CKD patients. Longer-term extension data continue to support durable efficacy beyond the initial study periods.

Is Roxadustat Safe for Long-Term Use in Kidney Disease?

Cardiovascular safety was a key concern during roxadustat's regulatory evaluation. In pooled Phase 3 analyses submitted to the FDA, there was a potential signal for major adverse cardiovascular events (MACE) and thromboembolic events in the non-dialysis-dependent CKD population compared to placebo. The FDA's Cardiovascular and Renal Drugs Advisory Committee voted against approval in 2021, and the FDA issued a Complete Response Letter. However, the European Medicines Agency (EMA) approved roxadustat (marketed as Evrenzo) in 2021, concluding that the benefit-risk balance was favorable when used according to the approved indication. The drug is also approved in Japan and China.

The most common adverse events with roxadustat in clinical trials include hyperkalemia, nausea, and diarrhea. A notable advantage is the reduction in intravenous iron requirements, as roxadustat suppresses hepcidin and improves oral iron absorption. This is clinically significant given emerging evidence that chronic high-dose IV iron may promote oxidative stress and infection risk in dialysis patients. In the DOLOMITES study (non-dialysis CKD patients), roxadustat demonstrated non-inferiority to darbepoetin alfa for hemoglobin response, with lower hepcidin levels and reduced IV iron use. Nephrology guidelines, including those from KDIGO, continue to evaluate how HIF-PHIs should be positioned relative to traditional ESAs as more long-term data accumulate.